Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycogen debranching enzyme (GDE) is a crucial enzyme in glycogen metabolism, responsible for the breakdown of branched glycogen molecules to release glucose. It is a multifunctional, bifunctional enzyme with two distinct catalytic activities: transferase and glucosidase. GDE works alongside glycogen phosphorylase to mobilize glucose from glycogen stores by transferring three glucose residues from the branch to another chain and cleaving the remaining α-1,6 linkage to release free glucose. Deficiency or mutations in AGL cause glycogen storage disease type III (GSDIII), characterized by hepatomegaly, hypoglycemia, and myopathy.
Inhibition of glycogen debranching enzyme activity (GDE) to modulate glucose release from glycogen stores. Currently, there are no known drugs that target GDE. The mechanism would be inhibition to slow down glycogen breakdown in certain diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycogen Debranching Enzyme (None).